Investigational Immunotherapy Trials for Prostate Cancer

The Keynote prostate cancer clinical trials are studying an investigational drug, pembrolizumab, to see if it is safe and if it helps slow down or stop the growth of prostate cancer. This type of cancer begins when cells inside the prostate gland start to grow rapidly. As more cancer cells grow, they form a tumor and can potentially spread to other areas of the body. 

Cancer that has spread beyond the prostate is known as metastatic prostate cancer. Male hormones (such as testosterone) help prostate cancer grow, so men with metastatic prostate cancer usually get hormone therapy as their first treatment. This treatment aims to lower the body’s levels of male hormones to shrink the cancer in the prostate and other areas where it has spread. However, prostate cancer may eventually grow and require more treatments to help stop or slow down the disease. This is when the prostate cancer is called metastatic castration resistant prostate cancer (mCRPC). 

Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

You can also call our clinical trial information center at 1-888-577-8839 to learn more.

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.